These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39471972)

  • 1. Integrated all-atom and coarse-grained simulations uncover structural, dynamics and energetic shifts in SARS-CoV-2 JN.1 and BA.2.86 variants.
    Sharma A; Maurya S; Tripathi T; Padhi AK
    Acta Trop; 2024 Dec; 260():107444. PubMed ID: 39471972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular insights into the binding interactions and energetics of the omicron spike variant with hACE2 and a neutralizing antibody.
    Kumar V; Shefrin S; Sundar D
    J Struct Biol; 2024 Jun; 216(2):108087. PubMed ID: 38494148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic study of the transmission pattern of the SARS-CoV-2 omicron variant.
    An K; Yang X; Luo M; Yan J; Xu P; Zhang H; Li Y; Wu S; Warshel A; Bai C
    Proteins; 2024 Jun; 92(6):705-719. PubMed ID: 38183172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ensemble-Based Mutational Profiling and Network Analysis of the SARS-CoV-2 Spike Omicron XBB Lineages for Interactions with the ACE2 Receptor and Antibodies: Cooperation of Binding Hotspots in Mediating Epistatic Couplings Underlies Binding Mechanism and Immune Escape.
    Raisinghani N; Alshahrani M; Gupta G; Verkhivker G
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-sectional and longitudinal genotype to phenotype surveillance of SARS-CoV-2 variants over the first four years of the COVID-19 pandemic.
    Akerman A; Fichter C; Milogiannakis V; Esneau C; Silva MR; Ison T; Lopez JA; Naing Z; Caguicla J; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Boss T; Condylios A; Yeang M; Sato K; Bartlett NN; Darley D; Matthews G; Stark DJ; Promsri S; Rawlinson WD; Murrell B; Kelleher AD; Dwyer D; Sintchenko V; Kok J; Ellis S; Marris K; Knight E; Hoad VC; Irving DO; Gosbell I; Brilot F; Wood J; Aggarwal A; Turville SG
    EBioMedicine; 2024 Dec; 110():105415. PubMed ID: 39549677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains.
    Starr TN; Greaney AJ; Stewart CM; Walls AC; Hannon WW; Veesler D; Bloom JD
    PLoS Pathog; 2022 Nov; 18(11):e1010951. PubMed ID: 36399443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective clinical performance of CoVarScan in identifying SARS-CoV-2 Omicron subvariants.
    Zhu K; Sah M; Mahimainathan L; Liu Y; Xing C; Roush K; Clark A; SoRelle J
    Microbiol Spectr; 2024 Dec; ():e0138524. PubMed ID: 39660915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Free Energy Perturbation Calculations of Mutation Effects on SARS-CoV-2 RBD::ACE2 Binding Affinity.
    Sergeeva AP; Katsamba PS; Liao J; Sampson JM; Bahna F; Mannepalli S; Morano NC; Shapiro L; Friesner RA; Honig B
    J Mol Biol; 2023 Aug; 435(15):168187. PubMed ID: 37355034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C→U transition biases in SARS-CoV-2: still rampant 4 years from the start of the COVID-19 pandemic.
    Simmonds P
    mBio; 2024 Dec; 15(12):e0249324. PubMed ID: 39475243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid spread of the SARS-CoV-2 Omicron XDR lineage derived from recombination between XBB and BA.2.86 subvariants circulating in Brazil in late 2023.
    Arantes I; Ito K; Gomes M; Carvalho FCd; Ferreira de Almeida WA; Khouri R; Miyajima F; Wallau GL; Naveca FG; Pereira EC; ; Mendonça Siqueira M; Resende PC; Bello G
    Microbiol Spectr; 2024 Nov; ():e0119324. PubMed ID: 39611827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broad Neutralization Capacity of an Engineered Thermostable Three-Helix Angiotensin-Converting Enzyme 2 Polypeptide Targeting the Receptor-Binding Domain of SARS-CoV-2.
    Cavazzini D; Levati E; Germani S; Ta BL; Monica L; Bolchi A; Donofrio G; Garrapa V; Ottonello S; Montanini B
    Int J Mol Sci; 2024 Nov; 25(22):. PubMed ID: 39596383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring New COVID-19 Incertitude: JN.1 Variant- JN.1: The Queer Bird among Omicron Sublineages.
    Ray SK; Mukherjee S
    Infect Disord Drug Targets; 2025; 25(1):e270624231369. PubMed ID: 38939989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing FDA-approved drugs for COVID-19: targeting the main protease through multi-phase
    Metwaly AM; Elkaeed EB; Alsfouk AA; Ibrahim IM; Elkady H; Eissa IH
    Antivir Ther; 2024 Dec; 29(6):13596535241305536. PubMed ID: 39639531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular insights into Dalbavancin's blockade of ACE2-spike protein interaction in SARS-CoV-2.
    Liu Z; Lv Y; Luo S; Duan L
    Phys Chem Chem Phys; 2024 Dec; 26(48):29853-29862. PubMed ID: 39607377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Into the Cauldron of the Variant Soup: Insights into the Molecular Epidemiology and Transition to Endemicity of SARS-CoV-2 in Cyprus (November 2022-February 2024).
    Chrysostomou AC; The Comessar Network ; Kostrikis LG
    Viruses; 2024 Oct; 16(11):. PubMed ID: 39599801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benchmark Investigation of SARS-CoV-2 Mutants' Immune Escape with 2B04 Murine Antibody: A Step Towards Unraveling a Larger Picture.
    Kapusta K; McGowan A; Banerjee S; Wang J; Kolodziejczyk W; Leszczynski J
    Curr Issues Mol Biol; 2024 Nov; 46(11):12550-12573. PubMed ID: 39590339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural bases for the higher adherence to ACE2 conferred by the SARS-CoV-2 spike Q498Y substitution.
    Erausquin E; Glaser F; Fernández-Recio J; López-Sagaseta J
    Acta Crystallogr D Struct Biol; 2022 Sep; 78(Pt 9):1156-1170. PubMed ID: 36048155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Australia in 2030: what is our path to health for all?
    Backholer K; Baum F; Finlay SM; Friel S; Giles-Corti B; Jones A; Patrick R; Shill J; Townsend B; Armstrong F; Baker P; Bowen K; Browne J; Büsst C; Butt A; Canuto K; Canuto K; Capon A; Corben K; Daube M; Goldfeld S; Grenfell R; Gunn L; Harris P; Horton K; Keane L; Lacy-Nichols J; Lo SN; Lovett RW; Lowe M; Martin JE; Neal N; Peeters A; Pettman T; Thoms A; Thow AMT; Timperio A; Williams C; Wright A; Zapata-Diomedi B; Demaio S
    Med J Aust; 2021 May; 214 Suppl 8():S5-S40. PubMed ID: 33934362
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.